Regeneron Pharmaceuticals Inc (REGN): Is This Eye Drug Worth The Hype?

Page 1 of 2

Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions. This has been corrected and Motley Fool sincerely apologizes for the error.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.

Regeneron Pharmaceuticals is a $25 billion biopharmaceutical company with three approved products and annual sales of $1.59 billion. Right away, that ratio not might look right, as a $25 billion company should have more revenue than $1.59 billion. But, its stock price is counting on growth, as it has 13 products being tested in clinical trials, and three different drugs in Phase 3 (five total studies).

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Taking a look at Eylea

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of the most promising drug companies in the market, and it is because of Eylea. Currently, Eylea is used to treat “wet” age-related macular degeneration, the leading cause of blindness in the elderly. It is approved in the U.S., and Regeneron markets the drug exclusively – but Bayer markets the drug oversees and receives a royalty on oversees revenue.

While Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Bayer are partners in developing and marketing Eylea, there’s no question Eylea has been developed using the technology of Regeneron and is primarily Regeneron’s drug. Its most direct competition comes from RocheHoldings‘  drug Lucentis. Roche is the world’s largest vaccine developer, and when Eylea was launched many feared that it would not be able to compete with the presence of Roche and its drug.

Eylea set to expand

Eylea is quickly replacing all competition (including Roche’s Lucentis) as both Regeneron Pharmaceuticals Inc (NASDAQ:REGN)and Bayer have done a great job marketing the drug. Not to mention, Eylea is superior in that it only has to be injected once every two months; compared to monthly like other drugs.

However, there is another drug in the works that must be mentioned, and that is Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)’ drug Optina. This drug treats the same condition, but instead of a needle to the eye, it is taken in pill form to repair blood vessels. But, Optina is still in clinical trials, awaiting data, and there are serious doubts the drug will be effective.

If Regeneron Pharmaceuticals Inc (NASDAQ:REGN) believed Optina would challenge its future sales, there’s no doubt it would buy the company. Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) trades at a market cap of just $220 million while Regeneron is a $25 billion powerhouse. And Regeneron has an incredible pipeline along with a drug that is growing and expanding. In short, it has the cash.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), not counting proceeds to Bayer, is expected to achieve revenue of $1.3 billion this year. The drug is well on its way to blockbuster status and has accomplished this feat with the one application. Therefore, its 10% rise last Thursday shouldn’t serve as a surprise; as the data shows that Eylea works on other applications as well.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) produced positive top-line data for the treatment of myopic choroidal neovascularization (mCNV) in a Phase 3 trial. mCNV is a disease where abnormal blood vessels grow into the retina in people who are severely short-sighted. This disease is quite different from age-related macular degeneration, showing the potential diversification of the product.

The addition of mCNV won’t create billions in additional sales, but analysts predict that it could boost sales another $200 million in the U.S. alone. Last year, Roche’s Lucentis saw sales of $1.5 billion and it treats wet age related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Basically, it treats a variety of diseases of the eye, and its revenue is expected to drop by about half in the next year. This cut is because of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and the fact that Eylea is well on its way to offering a wide range of treatments that are superior to existing treatments.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

The 10 Biggest Tax Havens in the World to Stash Your Money

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!